Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 1125-1131

  Tanaka, Katsuhiro ^a   Sonoo, Hiroshi ^a   Kurebayashi, Junichi ^a   Nomura, Tsunehisa ^a   Ohkubo, Sumiko ^a   Yamamoto, Yutaka ^a   Yamamoto, Shigeru ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CD36 ANTIGEN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER INFILTRATION; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SCHOOL CHILD; THYROID PAPILLARY CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADOLESCENT; ADULT; AGED; ANGIOPOIETIN-2; ANTIGENS, CD36; CARCINOMA, PAPILLARY; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR, TIE-2; THROMBOSPONDIN 1; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036096954     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Angiogenesis in cancer and other diseases
2. The biology of vascular endothelial growth factor
3. Angiopoietin-1, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
4. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis?
5. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
6. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor
7. Inhibition of angiogenesis by thrombospondin-2
8. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
9. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
10. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
11. Regulation of tumor growth and metastasis by thrombospondin-1
12. Cell attachment to thrombospondin: The role of Arg-Gly-Asp, calcium, and integrin receptors
13. Rapid purification and partial characterization of human platelet glycoprotein IIIb
14. r 80,000/105,000 receptor
15. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro
16. Thrombospondin-1 expression in bladder cancer: Association with p53 alternations, tumor angiogenesis, and tumor progression
17. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
18. Thrombospondin-1 expression in oral squamous cell carcinomas: Correlations with tumor vascularity, clinicopathological features and survival
19. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers
20. Plasma thrombospondin levels in patients with colorectal carcinoma
21. Expression of thrombospondin-1 in pancreatic carcinoma: Correlation with microvessel density
22. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma
23. Stromal expression of thrombospondin-1 is correlated with growth and metastasis of human gallbladder carcinoma
24. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor
25. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1
26. Thrombospondin-1 promotes α3β1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells
27. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast
28. Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor
29. The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer
30. Immunohistochemical study of thrombospondin and its receptor αvβ3 and CD36 in normal thyroid and in thyroid tumours
31. Expression of the thrombospondin-1 receptor CD36 is correlated with decreased stromal vascularisation in colon cancer
32. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects
33. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma
34. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
35. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma
36. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma
37. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases
38. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis
39. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-s as an early marker of tumor angiogenesis
40. The angiopoietins, tie2 and vascular endothelial growth factor differently expressed in the transformation of normal lung to non-small cell lung carcinomas
41. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis
42. Changes in the immunohistochemical localisation of fibroblast growth factor-s, transforming growth factor-β1 and thrombospondin-1 are associated with early angiogenic events in the hyper-plastic rat thyroid
43. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma
44. Independent association of angiogenesis index with outcome in prostate cancer
45. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989
46. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features
47. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
48. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53-null thyroid carcinoma cell line in vivo
49. Thrombospondin-1 and transforming growth factor-β1 promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system
50. Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma
51. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas
52. Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis
53. Two competing influences that may explain concomitant tumor resistance